Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: Renal Impairment

Multiple Myeloma: Renal Impairment

Lenalidomide Refractory Patients

Lenalidomide Refractory Patients

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Multiple Myeloma

Multiple Myeloma

An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments

An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments

No Rebound Effect Post Clopidogrel Withdrawal

No Rebound Effect Post Clopidogrel Withdrawal

PCSK9 inhibitors and ACS

PCSK9 inhibitors and ACS

Evaluation of lipid management following ACS

Evaluation of lipid management following ACS

The InRange Study

The InRange Study

Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

Proprotein convertase subtilisin/kexin type 9 inhibitors for heterozygous familial hypercholesterolemia: A clinical practice experience from the SAFEHEART registry

SoliMix Study Results Summary

SoliMix Study Results Summary